ATE77959T1 - Tumor-nekrose-faktor-formulierung und ihre herstellung. - Google Patents

Tumor-nekrose-faktor-formulierung und ihre herstellung.

Info

Publication number
ATE77959T1
ATE77959T1 AT87304703T AT87304703T ATE77959T1 AT E77959 T1 ATE77959 T1 AT E77959T1 AT 87304703 T AT87304703 T AT 87304703T AT 87304703 T AT87304703 T AT 87304703T AT E77959 T1 ATE77959 T1 AT E77959T1
Authority
AT
Austria
Prior art keywords
production
necrosis factor
tumor necrosis
factor formulation
unsubstituted
Prior art date
Application number
AT87304703T
Other languages
English (en)
Inventor
Nandini Katre
James William Thomson
Michael James Knauf
Original Assignee
Cetus Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cetus Corp filed Critical Cetus Corp
Application granted granted Critical
Publication of ATE77959T1 publication Critical patent/ATE77959T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT87304703T 1986-05-29 1987-05-27 Tumor-nekrose-faktor-formulierung und ihre herstellung. ATE77959T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86876686A 1986-05-29 1986-05-29
EP87304703A EP0247860B1 (de) 1986-05-29 1987-05-27 Tumor-Nekrose-Faktor-Formulierung und ihre Herstellung

Publications (1)

Publication Number Publication Date
ATE77959T1 true ATE77959T1 (de) 1992-07-15

Family

ID=25352278

Family Applications (1)

Application Number Title Priority Date Filing Date
AT87304703T ATE77959T1 (de) 1986-05-29 1987-05-27 Tumor-nekrose-faktor-formulierung und ihre herstellung.

Country Status (9)

Country Link
EP (1) EP0247860B1 (de)
JP (1) JPS62289522A (de)
AT (1) ATE77959T1 (de)
AU (1) AU595321B2 (de)
CA (1) CA1283046C (de)
DE (1) DE3780218T2 (de)
DK (1) DK277187A (de)
FI (1) FI872393A (de)
NO (1) NO872227L (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5091176A (en) * 1988-11-02 1992-02-25 W. R. Grace & Co.-Conn. Polymer-modified peptide drugs having enhanced biological and pharmacological activities
US5510418A (en) * 1988-11-21 1996-04-23 Collagen Corporation Glycosaminoglycan-synthetic polymer conjugates
US5565519A (en) * 1988-11-21 1996-10-15 Collagen Corporation Clear, chemically modified collagen-synthetic polymer conjugates for ophthalmic applications
US5162430A (en) * 1988-11-21 1992-11-10 Collagen Corporation Collagen-polymer conjugates
US5306500A (en) * 1988-11-21 1994-04-26 Collagen Corporation Method of augmenting tissue with collagen-polymer conjugates
US6166183A (en) * 1992-11-30 2000-12-26 Kirin-Amgen, Inc. Chemically-modified G-CSF
DE68925966T2 (de) * 1988-12-22 1996-08-29 Kirin Amgen Inc Chemisch modifizierte granulocytenkolonie erregender faktor
CA2047730A1 (en) * 1989-02-24 1990-08-25 Carl W. Gilbert Immobilized cytokines
DK0393438T3 (da) * 1989-04-21 2005-05-30 Amgen Inc TNF-receptor, TNF-bindende proteiner og DNAér, der koder herfor
US7264944B1 (en) 1989-04-21 2007-09-04 Amgen Inc. TNF receptors, TNF binding proteins and DNAs coding for them
US6221675B1 (en) 1989-04-21 2001-04-24 Amgen, Inc. TNF receptors, TNF binding proteins and DNAs coding for them
US5166322A (en) * 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
IL95031A (en) 1989-07-18 2007-03-08 Amgen Inc A method of producing a recombinant human necrotic factor absorber
US6143866A (en) * 1989-07-18 2000-11-07 Amgen, Inc. Tumor necrosis factor (TNF) inhibitor and method for obtaining the same
ATE118686T1 (de) * 1989-08-07 1995-03-15 Debio Rech Pharma Sa Biologisch wirksame polymere arzneistoffderivate.
DE3936777A1 (de) * 1989-11-04 1991-05-08 Basf Ag Quervernetzte tumor-nekrose-faktoren
JPH04218000A (ja) * 1990-02-13 1992-08-07 Kirin Amgen Inc 修飾ポリペプチド
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
DE69110133T2 (de) * 1990-10-18 1996-02-15 Univ Texas Herstellung und charakterisierung der liposomformulierungen des tumornekrosefaktors.
US5653974A (en) * 1990-10-18 1997-08-05 Board Of Regents,The University Of Texas System Preparation and characterization of liposomal formulations of tumor necrosis factor
KR100234520B1 (ko) * 1991-01-18 1999-12-15 그레고리 아보트 종양괴사인자 매개병 치료용 의약품 조성물
AU3423293A (en) * 1991-12-19 1993-07-19 Baylor College Of Medicine Pva or peg conjugates of peptides for epitope-specific immunosuppression
US5446090A (en) * 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
US5629384A (en) * 1994-05-17 1997-05-13 Consiglio Nazionale Delle Ricerche Polymers of N-acryloylmorpholine activated at one end and conjugates with bioactive materials and surfaces
US20030053982A1 (en) 1994-09-26 2003-03-20 Kinstler Olaf B. N-terminally chemically modified protein compositions and methods
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
TW555765B (en) 1996-07-09 2003-10-01 Amgen Inc Low molecular weight soluble tumor necrosis factor type-I and type-II proteins
IT1291114B1 (it) * 1997-03-20 1998-12-29 Angeletti P Ist Richerche Bio Varianti del fattore neurotrofico ciliare (cntf) con migliorata selettivita' al recettore, e metodo per la loro selezione
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
DE10144252A1 (de) * 2001-08-31 2003-03-27 Fraunhofer Ges Forschung Nanopartikel mit daran immobilisiertem biologisch aktivem TNF
US7179891B2 (en) 2002-03-25 2007-02-20 Tadanori Mayumi Physiologically active complex
JP4177604B2 (ja) * 2002-03-25 2008-11-05 株式会社林原生物化学研究所 生理活性複合体
TW200526780A (en) 2004-01-06 2005-08-16 Hayashibara Biochem Lab TNF antagonists and TNF inhibitors comprising the same as the active ingredient
US20070065514A1 (en) * 2005-09-22 2007-03-22 Howell Mark D Method for enhancing immune responses in mammals
CN101219219B (zh) * 2007-01-10 2013-02-13 北京普罗吉生物科技发展有限公司 包含血管抑素或其片段的复合物、其制备方法及应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4414147A (en) * 1981-04-17 1983-11-08 Massachusetts Institute Of Technology Methods of decreasing the hydrophobicity of fibroblast and other interferons
DE3380726D1 (en) * 1982-06-24 1989-11-23 Japan Chem Res Long-acting composition
EP0154316B1 (de) * 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemisch modifizierte Lymphokine und Verfahren zu ihrer Herstellung
AU580431B2 (en) * 1985-06-26 1989-01-12 Cetus Corp Solubilization of proteins for pharmaceutical compositions using polymer conjugation
DE3676670D1 (de) * 1985-06-26 1991-02-07 Cetus Corp Solubilisierung von proteinen fuer pharmazeutische zusammensetzungen mittels polymerkonjugierung.

Also Published As

Publication number Publication date
AU595321B2 (en) 1990-03-29
NO872227L (no) 1987-11-30
AU7347987A (en) 1987-12-03
FI872393A (fi) 1987-11-30
NO872227D0 (no) 1987-05-27
EP0247860A3 (en) 1989-10-11
EP0247860A2 (de) 1987-12-02
JPS62289522A (ja) 1987-12-16
DK277187D0 (da) 1987-05-29
DK277187A (da) 1987-12-01
DE3780218D1 (de) 1992-08-13
FI872393A0 (fi) 1987-05-28
EP0247860B1 (de) 1992-07-08
CA1283046C (en) 1991-04-16
DE3780218T2 (de) 1992-12-17

Similar Documents

Publication Publication Date Title
ATE77959T1 (de) Tumor-nekrose-faktor-formulierung und ihre herstellung.
ES2061589T3 (es) Sistema de liberacion de principios activos implantable y biologicamente degradable.
DE69123795D1 (de) Pharmazeutische Zusammensetzung zur rektalen Verabreichung von Wirkstoffen mit topischer medizinischer Wirkung im Dickdarmniveau
IT1141954B (it) Procedimento per ottenere eparine di basso peso molecolare dotate di proprieta' farmacologiche elevate,e prodotto cosi' ottenuto
DE59202537D1 (de) Feste pharmazeutische Retardform.
NZ221484A (en) Starburst polymer conjugates as carriers for agricultural, pharmaceutical and other materials
ITMI922603A1 (it) Composizioni farmaceutiche comprendenti un farmaco, una sostanza polimerica reticolata, un olio ed un agente tensioattivo
DE3576495D1 (de) 5-(3,5-disubstituierte phenylazo)-2-hydroxyphenylessigsaeuren, deren salze und lactone, und diese enthaltende pharmazeutische zusammensetzungen.
EP0169443A3 (de) Trizyklisch Dihydropyridazinone und diese enthaltende pharmazeutische Zusammensetzungen
DE3773440D1 (de) Pharmazeutische zusammensetzungen fuer suppositorien.
FI854511A0 (fi) Vattenloesliga polymerer.
FR2416247A1 (fr) Nouvelles compositions extrudables a base de polymeres imidazolidiniques et de plastifiants
DE69003466D1 (de) Substituierte Thienopyrimidin-Derivate, deren Herstellung, pharmazeutische Zusammensetzungen und medizinische Verwendung.
JPS5460395A (en) Preparation of modified polyester
JPS56163144A (en) Polyoxymethylene composition
ATE19077T1 (de) Thiophen-derivat mit mucoregulatorischer und anti-husten-wirkung, verfahren zu seiner herstellung und dieses enthaltende pharmazeutische zusammensetzungen.
ES2140596T3 (es) 17-desoxi-corticoide-21-(esteres de acidos carboxilicos), procedimiento para su preparacion y medicamentos que los contienen.
IT1266787B1 (it) Composizioni terapeutiche ad attivita' antitumorale a base di derivati 1,3,8,10 tetrasostituiti del 4,5,6,7-tetratiocino-(1,2-b: 3,4-b')-
DE164635T1 (de) Imidazothiazolmethylenacetohydrazid-derivate, ihre herstellung und pharmazeutische zusammensetzungen mit diuretischer wirkung.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EEIH Change in the person of patent owner
REN Ceased due to non-payment of the annual fee